Commerzbank Aktiengesellschaft’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-612,886
Closed -$7.62M 1035
2016
Q4
$7.62M Sell
612,886
-11,302
-2% -$136K 0.11% 167
2016
Q3
$8.54M Sell
624,188
-5,006
-0.8% -$50.3K 0.14% 140
2016
Q2
$4.65K Buy
629,194
+232
+0% +$1.74K 0.03% 244
2016
Q1
$4.02M Buy
628,962
+605,067
+2,532% +$3.39M 0.03% 270
2015
Q4
$149K Buy
+23,895
New +$157K ﹤0.01% 1081
2015
Q3
Sell
-48,294
Closed -$399K 1213
2015
Q2
$399K Buy
48,294
+4,367
+10% +$38.6K ﹤0.01% 1030
2015
Q1
$362K Sell
43,927
-316,200
-88% -$2.34M ﹤0.01% 1011
2014
Q4
$2.47M Sell
360,127
-76,257
-17% -$477K 0.02% 602
2014
Q3
$2.36M Sell
436,384
-112,094
-20% -$655K 0.01% 696
2014
Q2
$3.49M Buy
548,478
+220,604
+67% +$1.52M 0.02% 576
2014
Q1
$2.64M Buy
327,874
+206,412
+170% +$1.61M 0.01% 638
2013
Q4
$898K Buy
121,462
+91,993
+312% +$497K ﹤0.01% 917
2013
Q3
$542K Buy
29,469
+11,429
+63% +$222K ﹤0.01% 964
2013
Q2
$316K Buy
+18,040
New +$320K ﹤0.01% 1224

Other funds holding ARIA

Commerzbank Aktiengesellschaft's ARIA Position: Q1 2017 in Review

Commerzbank Aktiengesellschaft sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 612,886 shares — an estimated $7.62M sold.

Commerzbank Aktiengesellschaft first reported a position in ARIA in Q2 2013 and held it in 14 quarters. The position peaked at $8.54M in Q3 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Commerzbank Aktiengesellschaft reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Commerzbank Aktiengesellschaft sold 612,886 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $7.62M.
  • Commerzbank Aktiengesellschaft first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 14 quarters.
  • Commerzbank Aktiengesellschaft's Ariad Pharmaceuticals Inc position peaked at $8.54M in Q3 2016.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q1 2017, filed 1 May 2017.